| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
S-17092 targets prolyl oligopeptidase (POP), a serine protease that cleaves proline-containing peptides. By inhibiting POP, S-17092 prevents the degradation of neuroactive peptides, leading to increased levels of these peptides in the brain. This mechanism is thought to underlie its potential neuroprotective and cognitive-enhancing effects.
|
|---|---|
| ln Vitro |
S-17092 is a potent and selective inhibitor of prolyl oligopeptidase (POP). It has demonstrated high affinity for POP and selectivity over other proteases. In vitro, it inhibits POP activity and prevents the degradation of POP substrates. Specific IC50 values are not detailed in the available literature.
|
| ln Vivo |
S-17092 has been studied in animal models for its potential neuroprotective and cognitive-enhancing effects. It has shown efficacy in models of cognitive impairment, suggesting it may improve learning and memory. It has also shown neuroprotective effects in models of neurodegeneration.
|
| Enzyme Assay |
The in vitro activity of S-17092 is assessed using enzyme inhibition assays with purified recombinant POP. The compound is incubated with the enzyme and a fluorogenic peptide substrate, and the extent of inhibition is measured. IC50 values are calculated from dose-response curves. Selectivity against other proteases is confirmed.
|
| Cell Assay |
Cell-based assays can be used to evaluate S-17092's effects on peptide levels. Cells or tissue homogenates are treated with S-17092, and the levels of POP substrates, such as substance P, are measured by ELISA or radioimmunoassay. The compound's ability to prevent peptide degradation is assessed.
|
| Animal Protocol |
S-17092 has been evaluated in animal models of cognitive impairment and neurodegeneration. In these studies, the compound is typically administered orally or intraperitoneally to rodents. Cognitive function is assessed using behavioral tests such as the Morris water maze or passive avoidance test. Neuroprotective effects are assessed by measuring neuronal survival and other biomarkers.
|
| ADME/Pharmacokinetics |
S-17092 has a molecular weight and formula that are not detailed in the available literature. It is a potent and selective prolyl oligopeptidase (POP) inhibitor. Purity is typically ≥98%. The compound is soluble in DMSO. Storage is recommended at -20°C. It is a research compound for studying POP function and potential therapeutic applications in cognitive disorders and neurodegeneration.
|
| Toxicity/Toxicokinetics |
S-17092 is a research compound and its full toxicological profile is not detailed in the available literature. As a POP inhibitor, it modulates neuroactive peptide levels, which could have various physiological effects. In animal studies, it has been used at various doses without significant adverse effects reported. Standard safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
S-17092 (CAS#: 176797-26-5) is a potent and selective inhibitor of prolyl oligopeptidase (POP), also known as prolyl endopeptidase (PREP). It is a research compound studied for its potential neuroprotective and cognitive-enhancing effects. By inhibiting POP, S-17092 increases the levels of neuroactive peptides involved in learning, memory, and neuroprotection. It is a valuable research tool for studying POP function and cognitive disorders.
|
| Molecular Formula |
C22H28N2O2S
|
|---|---|
| Molecular Weight |
384.54
|
| Exact Mass |
384.187
|
| CAS # |
176797-26-5
|
| PubChem CID |
9929984
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.358
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
27
|
| Complexity |
591
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1CC[C@H]2[C@@H](C1)C[C@H](N2C(=O)[C@@H]3C[C@H]3C4=CC=CC=C4)C(=O)N5CCSC5
|
| InChi Key |
NXSXRIHXEQSYEZ-KNJMJIDISA-N
|
| InChi Code |
InChI=1S/C22H28N2O2S/c25-21(18-13-17(18)15-6-2-1-3-7-15)24-19-9-5-4-8-16(19)12-20(24)22(26)23-10-11-27-14-23/h1-3,6-7,16-20H,4-5,8-14H2/t16-,17-,18+,19-,20-/m0/s1
|
| Chemical Name |
[(2S,3aS,7aS)-2-(1,3-thiazolidine-3-carbonyl)-2,3,3a,4,5,6,7,7a-octahydroindol-1-yl]-[(1R,2R)-2-phenylcyclopropyl]methanone
|
| Synonyms |
S17092; S 17092; S-17092
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~260.06 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6005 mL | 13.0025 mL | 26.0051 mL | |
| 5 mM | 0.5201 mL | 2.6005 mL | 5.2010 mL | |
| 10 mM | 0.2601 mL | 1.3003 mL | 2.6005 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
